Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2019

View Archived Issues

Passage Bio announces new gene therapy clinical program for infantile Krabbe disease

Promising preclinical data presented for 4D-C102 and 4D-310

Patient enrollment ongoing in phase I study of BIIB-100

Dermavant Sciences initiates phase III study of tapinarof for the treatment of plaque psoriasis

A-Alpha Bio receives grant to develop drugs for infectious diseases

Fragile X quick-ish fix?

First phase I results for anti-GITR antibody MK-4166 in patients with advanced solid tumors

DNA repair pipeline stretches from POLO to pre-preclinical

Jiangsu Hengrui Medicine's camrelizumab receives first approval in China for treatment of lymphoma

Merck & Co. identifies new IDO-1 inhibitors

EZH2 inhibitors disclosed by Constellation Pharmaceuticals

Angex Pharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

Bristol-Myers Squibb discloses integrin alphav antagonists

Respiratory syncytial virus inhibitors patented by Enanta Pharmaceuticals

Phase III studies of Xolair in chronic rhinosinusitis with nasal polyps meet coprimary endpoints

Promising antitumor activity of olaparib against heavily pretreated mCRPC with DDR gene defects

FDA responds to Oncology Venture's IND for proposed pivotal phase III study of LiPlaCis

Kite, Humanigen evaluate investigational combination therapy for lymphoma

Phase I results provided for JNJ-61186372 in non-small cell lung cancer

Avacta plans clinical trial of TMAC linker next year

Talaris presents quality-of-life data on FCR-001

Preliminary activity seen with U3-1402 in resistant EGFR-mutant non-small cell lung cancer

Gamida Cell presents clinical and translational data from phase I/II study of omidubicel

Phase II COPD study finds no effect of CHF-6001 on lung function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...